The current financial score of Outlook Therapeutics Inc is 5.70. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 8.70K, representing a year-over-year decrease of 99.42%, while its net profit experienced a year-over-year decrease of 0.83%.
The current valuation score of Outlook Therapeutics Inc is 9.45. Its current P/E ratio is -0.45, which is -209.40% below the recent high of 0.50 and -1575.99% above the recent low of -7.62.
The current earnings forecast score of Outlook Therapeutics Inc is 7.00. The average price target is 5.03, with a high of 10.50 and a low of 1.60.
The current price momentum score of Outlook Therapeutics Inc is 5.13. Currently, the stock price is trading between the resistance level at 0.62 and the support level at 0.42, making it suitable for range-bound swing trading.
The current institutional shareholding score of Outlook Therapeutics Inc is 3.00. The latest institutional shareholding proportion is 8.33%, representing a quarter-over-quarter increase of 40.96%.
The current risk assessment score of Outlook Therapeutics Inc is 2.72. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.